



CIN: L24100MH1988PLC343805

Reg. Office : Office No.9, K Raheja Prime Sagbaug Road,
Marol, Andheri (East), Mumbai - 400059

info@remediumlifecare.com

+91 8433895251



REMEDIUM LIFECARE LTD.

(Formerly known as "Roxy Exports Limited")

August 25, 2025

To,
Listing Department
BSE Ltd.
P.J. Towers, Dalal Street,
Mumbai — 400 001.

Sub: Press Release - Remedium Lifecare Charts 4X Growth Path with Strategic Focus on 4-Point Strategy.

Dear Sirs/Madam,

Please find enclosed herewith a copy of the press release from the Company for your information and records.

This information will also be hosted on the Company's website, at www.remlife.com

Thanking you,

Yours faithfully,

For Remedium Lifecare Limited

Adarsh Munjal
Whole Time Director
DIN:07304004
Encl: As Above



Press Release

Remedium Lifecare Charts 4X Growth Path with Strategic Focus on 4-Point Strategy

Mumbai, August 25, 2025: Remedium Lifecare Ltd., a rapidly growing player in the pharmaceutical supply chain and specialty chemicals sector, has successfully unveiled a strategic roadmap anchored on a 4-point strategy.

- The first pillar is advanced manufacturing, focused on upgrading existing CDMO (Contract Development & Manufacturing Organization) facilities and expanding capacity to meet rising global demand. Backward integration initiatives will further optimize costs and ensure higher margins.
- The second pillar is global export expansion with plans to strengthen its international footprint by entering new geographies and deepening its presence in existing markets. Enhanced supply chain capabilities and working capital deployment will support seamless global operations.
- The third pillar is innovation and R&D excellence, supported by the establishment of a dedicated quality control laboratory and scaled research across therapeutic areas such as anti-infectives, cardiovascular, and central nervous system (CNS) treatments. This will accelerate product development, ensure regulatory compliance, and bolster the company's innovation pipeline.
- The fourth pillar is product diversification, aimed at broadening the company's specialty chemical and pharmaceutical portfolio to serve evolving market needs, ensuring resilience against sectoral fluctuations and expanding revenue streams.

Adarsh Munjal, Managing Director of Remedium Lifecare Ltd., said, "This quarter marks a turning point for Remedium Lifecare Ltd. Delivering a PAT that surpasses our entire FY25 profit demonstrates the strength of our business model and operational agility. The successful Rights Issue and our focused 4-point strategy-driving manufacturing excellence, accelerating global exports, scaling R&D innovation, and broadening product diversification provide us with a powerful foundation to achieve 4X growth and create sustainable value for our stakeholders."

The company has kicked off FY26 on a strong note with a Profit After Tax (PAT) of ₹464.88 lakh in Q1, marking a 327% surge compared to the loss of ₹204.60 lakh in Q4 FY25. EBITDA has jumped by 508%, reflecting strong operational efficiency. Notably, this single-quarter performance has already doubled the company's entire FY25 PAT of ₹212.94 lakh, underscoring robust operational execution and financial discipline. The company also successfully concluded its oversubscribed Rights Issue, raising ₹47.88 crore against applications totalling ₹51.86 crore.

The company's strong Q1 performance, coupled with prudent capital deployment, positions Remedium Lifecare to deliver consistent profitability, improved margins, and accelerated global reach. By combining operational efficiency with a clear innovation focus, the company is poised to capture emerging opportunities across domestic and international markets.

About Remedium Lifecare Ltd.:

Founded in 1988, Remedium Lifecare Ltd. is a BSE-listed pharmaceutical company engaged in the trading and distribution of raw material as a supply chain management

for the pharmaceutical industry with an emphasis on quality, compliance and global reach, the company continues to expand its presence while playing a pivotal role in India's pharmaceutical ecosystem
